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Abstract
Background: Studies on persistence of benzodiazepine agonist (BZDA) withdrawal in older outpatients are few,
and few studies on long-term persistence over years have yet been published. To describe the persistence of
temazepam, zolpidem, and zopiclone (BZDA) withdrawal among older outpatients at 3 years from the beginning of
withdrawal, as well as any changes in use of other medications.
Methods: 92 outpatients (≥55 years) with primary insomnia, long-term BZDA use as hypnotics (mean duration of
BZDA use 9.9 ± 6.2 years), and willingness to withdraw from BZDAs each received either melatonin or a placebo
nightly for one month. During this period, BZDAs were meant to be gradually withdrawn. Sleep hygiene
counselling and psychosocial support were provided. Three years later, use of BZDAs and other medications was
determined by interview and confirmed from medical records.
Results: Of the original 92 outpatients, 83 (90%) participated in the 3-year survey (mean follow-up 3.3 ± 0.2 years).
The number of BZDA-free participants decreased from 34 (37%) at 6 months to 26 (28%; intention-to-treat) at
3 years, that of irregular BZDA users decreased from 44 (48%) at 6 months to 27 (29%) at 3 years, while that of
regular users increased from 11 (12%) at 6 months to 30 (33%) at 3 years (P = 0.001).
Those who were regular BZDA users at 3 years had at baseline (before withdrawal) higher BMI (P = 0.001) than did
other participants. At 3 years, the total number of medications remained unchanged for non-users (P = 0.432), but
increased for the irregular (P = 0.011) and regular users (P = 0.026) compared to baseline. At 3 years, compared to
baseline, use of antidepressants, dopamine agonists, melatonin, and NSAIDs/paracetamol was significantly more
common in the whole cohort, but their use did not differ between the BZDA-user subgroups. Randomization to
melatonin or placebo during BZDA withdrawal was unrelated to BZDA-withdrawal result.
Conclusions: At 3 years after withdrawal, the number of BZDA-free participants had decreased, but still one-third of the
subjects remained BZDA-free, and one-third had reduced their use. Successful BZDA withdrawal did not lead to any
increase in total number of medications; use of symptomatic medications in the whole cohort, however, did increase.
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Background
Long-term benzodiazepine agonist (BZDA) use can result
in adverse outcomes such as increased risk of falls, frac-
tures, cognitive decline, and mortality [1–3]. Prolonged
benzodiazepine use as a hypnotic is considered inappro-
priate, according to guidelines on pharmacotherapy in the
aged [4]. However, a considerable proportion of subjects
with insomnia using BZDA hypnotics on a nightly basis
for years do still experience sleep disturbances despite
hypnotic medication [5, 6]. In a primary-care population,
prevalence of BZDA hypnotic drug prescriptions is much
higher for multimorbid patients than for patients without
multimorbidity [7]. The prevalence of chronic BZDA use
is particularly high in nursing-home residents, it has
ranged in European nursing homes from 28% [8] to more
than 50% [9].
Meta-analyses of interventions for reducing inappropri-
ate long-term BZDA use in older adults have shown
supervised BZDA withdrawal augmented with psychother-
apy to be the most effective intervention, but for prag-
matic reasons, a patient-centred approach with individual
planning and monitoring or medication reviews is the rec-
ommendation [10, 11]. Very little data on the long-term
persistence of BZDA withdrawal results exist, as most of
the follow-ups have been short, 0.5 to 3 months [11]. Few
studies have reported follow-ups lasting 12 months or lon-
ger [11–13]. Morin et al. did a 24-month outcome study
among community-dwelling residents who had used as
hypnotics various benzodiazepine medicaments but not
the widely used Z-drugs: zopiclone or zolpidem [14].
Vicens et al. [15] compared, in a 3-year study, educational
methods with routine care in regard to cessation of benzo-
diazepine use. However, most of their patients seem to
have used benzodiazepines for indications other than as
hypnotics, and a medical withdrawal intervention group
was lacking. Furthermore, whether BZDA withdrawal can
affect the use of other central nervous system (CNS) -af-
fecting drugs remains unknown. Our outpatient study is
the first in which persistence of BZDA hypnotic (mainly
Z-drugs) discontinuation has been followed for up to
3 years in chronic BZDA users, after melatonin/placebo--
supported initial withdrawal.
We performed in older outpatients a psychosocially
supported BZDA withdrawal intervention as described
earlier [16]. BZDA withdrawal rapidly improved muscle
strength and balance, but failed to improve cognitive
performance [17, 18]. The present secondary data ana-
lysis aimed to study in patients of our original cohort
their long-term persistence of BZDA withdrawal and
possible changes in their medications. In short, our aim
was to describe the persistence of temazepam, zolpidem,
and zopiclone (BZDA) withdrawal among older outpa-
tients at 3 years from the beginning of withdrawal, as
well as any changes in their use of other medications.
Methods
Details of this temazepam, zopiclone, and zolpidem
withdrawal study, its participants, interventions, mea-
surements, and withdrawal results up to 6 months have
appeared elsewhere [16–18]. In short, the original Satauni
study was a randomized, double-blind, placebo-controlled,
parallel-group study on the efficacy of daily melatonin
(2 mg) in BZDA withdrawal during a one-month period
and during a double-blind 5-month follow-up. At baseline,
a physician provided individual psychological support and
sleep-hygiene counselling, including discussions about
regular sleep rhythm and factors influencing sleep. The
psychological support for all participants was continued
by a nurse who provided a supportive visit once a week
and was available by phone during the one-month
withdrawal (period). The participants had follow-up
meetings with a nurse at months 2 and 6, and with a
physician at month 6 after withdrawal initiation. After
this, the participants returned to normal, routine care
at their health centres.
The main inclusion criteria at baseline were primary
insomnia according to the criteria of the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) [19], age ≥ 55 years, and long-term (>
1 month) regular night-time use of temazepam, zopi-
clone, or zolpidem to treat primary insomnia. The key
exclusion criteria were BZDA use other than those uses
identified above, current use of antipsychotic or antiepi-
leptic medication, active alcohol or drug abuse or a his-
tory of abuse, anxiety disorder or other psychiatric
disorder, neurological disease, smoking more than ten
cigarettes a day, or autoimmune disease [16].
For the present 3-year follow-up study, we sent a letter
to all our 92 initial participants and invited them for a
follow-up meeting and measurements. The study nurse
(JS, MS) met the participants and interviewed them. If
participants were unable to schedule an in-person meet-
ing, the study nurse called each one on the telephone
and requested return of the completed questionnaire.
The Satauni study protocol was approved by the Ethics
Committee of Satakunta Hospital District (2§/7/2008)
and by the National Agency for Medicines of Finland (218/
2008) and registered to EudraCT (2008–0006795-30).
Written informed consent was received from each partici-
pant before the study began.
Measurements and data collection
The participants were asked to report, as part of the
questionnaire, all medicines used. The study nurse veri-
fied the data by interviewing and examining the medical
records. Full medication lists were collected at baseline
and at the 3-year follow-up point, BZDAs were collected
at baseline, at one and 6 months, and at the 3-year
follow-up points. Structured questionnaires provided
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demographic data (age, gender, body mass index), use of
alcohol, duration of BZDA use, exercise activity, living
conditions, educational level, occupational status, driver’s
licence, smoking, satisfaction with life, self-reported
health, and expected health 1 year later. Depressive symp-
toms were measured with the Geriatric Depression Scale
15-point version (GDS-15) [20].
Statistical analyses
For our persistence analysis of BZDA withdrawal results,
participants were categorized to non-users (no BZDA
use), irregular users (intermittent BZDA use but no daily
use), and regular users (daily users of BZDA) according
to their BZDA use at the 3-year follow-up. The percent-
ages of non-users, irregular users, and regular users were
calculated according to the intention-to-treat principle
from the number of original participants, 92.
For statistical analysis, each drug was coded according
to the Anatomical Therapeutic Chemical Classification
of Medicines (ATC) [21] codes and grouped into one of
the following groups: BZDA (N05BA, N05CD, N03AE01,
N05CF, A03CA), antipsychotics (N05A), antidepressants
(N06A, N06CA), antiepileptics and gabapentinoids (N03A),
dopamine agonists (N04 BC), melatonin (N05CH01), opi-
oids (N02A, R05DA, R05FA), antihistamines (R06A,
N05BB), and anticholinergics (see ref. [22] for full list). The
“CNS medication” variable combined these, excluding
BZDA and melatonin and a combination variable for
non-steroidal anti-inflammatory drugs (NSAID) (M01A)
and paracetamol (N02BE01).
Differences in baseline measurements between non-
users, irregular users, and regular users were tested by
chi-square and Fisher exact tests for variables measured
with nominal or ordinal scales, and by the Kruskal-Wal-
lis test for those non-normally distributed, or by
one-way analysis of variance with Tukey’s post-hoc tests
for normally distributed continuous variables. The nor-
mality of the distributions was tested by the Shapiro-
Wilk test. The Kruskal-Wallis test served to test
differences in the number of all medications between
groups; changes within groups were tested with the Wil-
coxon signed rank test. Changes in medication use were
analyzed with McNemar’s test, and logistic regression
analysis using generalized estimating equations.
P-values less than 0.05 were considered statistically
significant. The statistical analyses were performed with
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
Of those 92 who originally enrolled in the study, 83
(90%) participated in the 3-year follow-up interview. At
baseline, mean BZDA use was 9.9 ± 6.2 years. Nine par-
ticipants (10%) were lost during follow-up (Fig. 1). Of
these, two participants died, and one moved away before
the follow-up meeting. The mean follow-up time after
the beginning of BZDA withdrawal was 3.3 ± 0.2 years.
Baseline characteristics of the participants, grouped
according to use of BZDA at the 3-year follow-up, are in
Table 1. Regular BZDA users at 3 years had significantly
higher BMI (body mass index) at baseline than did
non-users (P = 0.004) or irregular users (P = 0.005). Add-
itionally, expected health a year later was less uniform in
non-users and irregular users than in regular users (P =
0.001). The participants’ characteristics, including the
BZDA (temazepam, zopiclone, zolpidem) they had used
as a hypnotic, were, however, poor predictors of
long-term withdrawal persistence (Fig. 1, Table 2).
Persistence of withdrawal results up to 3 years
The number of BZDA-free participants had decreased
from 34 (37%) at the 6-month follow-up to 26 (28%) at
3 years, and that of irregular BZDA users from 44 (48%)
at 6 months to 27 (29%). The number of nightly regular
users had increased from 11 (12%) at months to 30 (33%)
at 3 years (P = 0.001). Use of melatonin (vs. placebo) dur-
ing the BZDA withdrawal month was not related to BZDA
use after 3 years (Table 1). The persistence of withdrawal
from individual BZDAs is in Table 2.
Change in use of other drugs
BZDA withdrawal did not affect the total number of medi-
cations in the non-users’ group (P = 0.432) (Table 3). The
total number of medications of irregular users (P = 0.011)
and of regular users increased (P = 0.026) compared to
baseline. Of the various medications, use of paracetamol
or NSAIDs doubled in the whole cohort (P < 0.001), but
with no significant differences between the final BZDA
non-users, irregular users, and regular users. Similarly, use
of antidepressants and dopamine agonists increased
within 3 years in the cohort, but without a significant dif-
ference between these groups. The use of melatonin in-
creased, particularly for the BZDA non-users.
Discussion
To our knowledge, this is the lengthiest study to ever
report BZDA withdrawal results after medical with-
drawal intervention (melatonin or placebo) with its
follow-up of 3 years. Our cohort had a high follow-up
retention rate after a structured BZDA withdrawal inter-
vention in older outpatients, individuals who had for a
long time regularly used short-acting BZDAs as hyp-
notics. Most (85%) of our participants had used chronic-
ally short-acting “Z-drugs,” zopiclone or zolpidem, and
only 15% had temazepam as their nightly hypnotic. The
short-term (at 1 month) withdrawal results in this
cohort were good [16]. However, BZDA use increased
markedly over time after the withdrawal period.
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Three years after the one-month BZDA withdrawal
period, roughly one-third of the initial participants
remained non-users, one-third used BZDAs irregularly,
and one-third took BZDAs regularly as a hypnotic. The
withdrawal rates and persistence of the withdrawal
seemed to be similar irrespective of the hypnotic.
Controlled-release melatonin during the one-month
BZDA withdrawal period did not affect the long-term
BZDA-withdrawal result. One explanation for persist-
ence of BZDA withdrawal was the psychosocial support
during the first month and at 2 and 6 months for all par-
ticipants. The number of all medications (median four
drugs per patient at baseline) did not increase within
3 years in non-users, whereas during that period—for
irregular users and regular users—it increased. However,
the number of participants using antidepressants, dopa-
mine agonists, melatonin, and NSAIDs/paracetamol
increased in all groups. Worryingly, some long-acting
benzodiazepines and BZDA combination preparations
with anticholinergic antidepressants were prescribed by
the time of the 3-year follow-up.
Most patient characteristics at baseline were fairly
similar in all groups despite the patients’ differing BZDA
use at the 3-year follow-up point. Yet, higher BMI at
baseline, i.e., before start of withdrawal, was associated
at the 3-year follow-up with regular BZDA use. Higher
BMI may be associated with sleep apnoea, but treatment
more appropriate than BZDA would be weight loss and
positive airway pressure therapy. As no clear markers
as yet exist, it is, however, impossible to predict at
baseline who will be a successful BZDA withdrawer
and who will not.
Expected health between the groups at baseline was
not uniform. As there were no major differences in
majority background variables, we decided that BMI and
expected health were not clinically meaningful back-
ground variables to be adjusted for. Furthermore, small
sample size would have complicated the multivariate
analyses. Of note, most—meaning 23 of the 26 final
non-users (at 3 years)—had used BZDA hypnotics regu-
larly for at least 5 years before entering this withdrawal
study. Thus, even after their very long-time use, BZDA
hypnotics, at the usual therapeutic doses, may not
reduce the likelihood of withdrawal of a patient who is
well motivated. On the other hand, a clear distinction
arises, as pointed out, in withdrawal success between
Fig. 1 Flow of participants through the study: From recruitment to completion
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Table 1 Characteristics of participants at baseline and grouped by BZDA use data at the 3-year follow-up point (final non-users,
irregular users, and users of BZDA)
Non-users (N = 26) Irregular users (N = 27) Regular users (N = 30) P
Mean ± SD Mean ± SD Mean ± SD
Age (years) 66.3 ± 5.6 66.9 ± 6.2 65.9 ± 6.9 0.815
Body Mass Index (kg/m2)* 26.4 ± 3.8 26.5 ± 2.9 30.0 ± 4.9 0.001
Median [LQ, UQ] Median [LQ, UQ] Median [LQ, UQ]
Use of alcohol (doses/week) 0.9 [0, 5.5] 2.5 [0, 5.3] 0 [0, 2.0] 0.106
N (%) N (%) N (%)
BZDA use at baseline
< 5 years 3 (12) 3 (11) 4 (13) 0.989
5–10 years 13 (50) 13 (48) 16 (53)
≥ 10 years 10 (39) 11 (41) 10 (34)
Randomized to CRM/placebo during withdrawal 12/14 (46/54) 13/14 (48/52) 17/13 (57/43) 0.700
Gender, women/men 16/10 (62/38) 16/11 (59/41) 25/5 (83/17) 0.094
Exercise activity
Low 1 (4) 2 (7) 3 (10) 0.696
Medium 25 (96) 23 (85) 26 (87)
High 0 (0) 2 (7) 1 (3)
Living conditions
With another person 17 (65) 23 (85) 21 (70) 0.228
Alone 9 (35) 4 (15) 9 (30)
Education level
Basic 12 (46) 9 (33) 17 (59) 0.252
Middle grade 10 (38) 16 (59) 9 (31)
College or academic 4 (15) 2 (7) 3 (10)
Occupational status
Regular day shifts 4 (15) 1 (4) 6 (20) 0.357
Irregular day shifts, shift-work 2 (8) 1 (4) 2 (7)
Retired or unemployed 20 (77) 25 (93) 22 (73)
Drivers’s licence 23 (88) 24 (89) 26 (87) 1.000
Depression
Not depressed (GDS-15 sum score < 6) 25 (96) 25 (93) 24 (80) 0.139
Depressed (GDS-15 sum score≥ 6) 1 (4) 2 (7) 6 (20)
Smoking
Non-smoker 25 (96) 27 (100) 26 (87) 0.098
Smoker 1 (4) 0 (0) 4 (13)
Use of alcohol
Non-user 4 (15) 5 (19) 7 (24) 0.192
Once a month or more seldom 9 (34) 5 (19) 14 (48)
2–4 times a month 7 (27) 11 (42) 6 (21)
2 times a week or more often 6 (23) 5 (19) 2 (7)
Satisfaction with life
Very satisfied 4 (15) 4 (15) 2 (7) 0.871
Quite satisfied 14 (54) 16 (59) 16 (53)
Not satisfied, but not unhappy 6 (23) 6 (22) 10 (33)
Quite unhappy 2 (8) 1 (4) 2 (7)
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abusers of high doses of BZDAs and those using thera-
peutic doses as hypnotics [23].
All our patients were outpatients, and nine of them
could not be contacted for the 3-year follow-up; at least
two of them had died, and one moved away before the
3-year follow-up point. Here, percentages of withdrawal
persistence were calculated conservatively by the
intention-to-treat (ITT) principle, meaning comparison
of numbers withdrawing to those 92 who had entered
the withdrawal study. Thus, the true withdrawal persist-
ence could be somewhat better than reported here.
According to recent withdrawal studies, spontaneous
BZDA withdrawal rate without any interventions ranges
from 5 to 26% [10, 11, 15, 24]. The study other than
ours with a 3-year follow-up reporting the results of
educational withdrawal intervention [15], with one-time
counselling or with counselling combined with follow-
up meetings lasting between 2 and 3 weeks, produced
respective withdrawal rates of 41 and 39%. In their con-
trol group (routine care), 26% had withdrawn [15]. In
our study, the BZDA withdrawal rate was 28% at 3 years
after psychosocially supported BZDA withdrawal aug-
mented with melatonin.
Persistence of BZDA withdrawal over years might have
been better had psychosocial support continued after the
one-month period. Additionally, there exist several
BZDA withdrawal interventions with shorter follow-ups:
In Canada, counselling at a pharmacy produced a 27%
persistence rate of BZDA withdrawal and dose reduc-
tions for 11% of its participants at 6 months [24]. An
American study [25] randomized long-term BZDA users
into three groups, among which one group received
cognitive behavioural therapy, one placebo therapy
(biofeedback), and one received physician-given counsel-
ling for gradual BZDA withdrawal. In all groups, the
BZDA use decreased 84% compared to baseline, and
Table 1 Characteristics of participants at baseline and grouped by BZDA use data at the 3-year follow-up point (final non-users,
irregular users, and users of BZDA) (Continued)
Non-users (N = 26) Irregular users (N = 27) Regular users (N = 30) P
Mean ± SD Mean ± SD Mean ± SD
Age (years) 66.3 ± 5.6 66.9 ± 6.2 65.9 ± 6.9 0.815
Body Mass Index (kg/m2)* 26.4 ± 3.8 26.5 ± 2.9 30.0 ± 4.9 0.001
Median [LQ, UQ] Median [LQ, UQ] Median [LQ, UQ]
Use of alcohol (doses/week) 0.9 [0, 5.5] 2.5 [0, 5.3] 0 [0, 2.0] 0.106
N (%) N (%) N (%)
Self-reported health
Good 6 (23) 5 (19) 5 (17) 0.855
Fair 15 (58) 19 (70) 21 (70)
Poor 5 (19) 3 (11) 4 (13)
Expected health a year later#
Healthier than now 6 (23) 3 (11) 13 (43) 0.001
No change 18 (69) 23 (85) 10 (33)
A bit worse than now 2 (8) 1 (4) 7 (23)
*Significant differences in final non-users vs. regular users (P = 0.004) and final irregular users vs. regular users (P = 0.005)
#Significant differences in final non-users vs. regular users (P = 0.029) and final irregular users vs. regular users (P < 0.001)
P = Statistical significance of difference between final non-users, final irregular users, and final regular users
LQ Lower quartile, UQ Upper quartile, BZDA Benzodiazepine agonist, CRM Controlled-release melatonin, GDS Geriatric Depression Scale
Table 2 Number of BZDA prescriptions at baseline and at 1-month, 6-month, and 3-year follow-ups grouped by the BZDA used at
baseline and withdrawal status data at 3-year follow-up (non-users, irregular users, and regular BZDA users)
Zopiclone Zolpidem Temazepam Other BZDA Total BZDA users
Non-users of any BZDA Irregular Regular Irregular Regular Irregular Regular Irregular Regular
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Baseline (92) 0 (0) 0 (0) 52 (57) 0 (0) 26 (28) 0 (0) 14 (15) 0 (0) 0 (0) 92 (100)
1-month (90) 70 (78) 8 (9) 1 (1) 4 (4) 0 (0) 6 (7) 1 (1) 0 (0) 0 (0) 20 (22)
6-month (89) 34 (38) 25 (48) 6 (12) 12 (46) 2 (8) 7 (50) 3 (21) 0 (0) 0 (0) 55 (62)
3-year (83) 26 (31) 14 (27) 15 (29) 5 (19) 10 (38) 6 (43) 5 (36) 7a (8) 1b (1) 57 (69)
aoxazepam (N = 4), alprazolam (N = 1), diazepam (N = 1) and clonazepam (N = 1)
bchlordiazepoxide with amitriptyline combination preparation (N = 1)
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Table 3 Use of medications, especially those with CNS effects, at baseline (before withdrawal) and at 3-year follow-up. Participants
are grouped by BZDA withdrawal status at 3 years (non-users, irregular users, regular users). P is for baseline vs. 3-year follow-up
Non-users (N = 26) Irregular users (N = 27) Regular users (N = 30) P (between groups)
Median [LQ,UQ] Median [LQ,UQ] Median [LQ,UQ]
Number of all medications
Baseline 4 [3, 5] 4 [4, 5] 4 [3, 6] 0.767
3-year follow-up 4 [2, 6] 5 [3, 7] 5 [3, 7] 0.222
P 0.432 0.011 0.026
Number of concomitant CNS medicationsa
Baseline 0 [0, 1] 0 [0, 1] 0 [0, 1] 0.744
3-year follow-up 1 [0, 1] 0 [0, 1] 0 [0, 1] 0.286
P 0.268 0.307 0.827
Users of medications groups N (%) N (%) N (%)
Antipsychotics
Baseline 0 (0) 0 (0) 0 (0) 1.000
3-year follow-up 0 (0) 1 (4) 1 (3) 1.000
P 0.157
Antidepressants
Baseline 4 (15) 7 (26) 6 (20) 0.634
3-year follow-up 9 (34) 11 (41) 9 (30) 0.677
P 0.006
Antiepileptics, gabapentinoids
Baseline 1 (4) 1 (4) 1 (3) 1.000
3-year follow-up 0 (0) 1 (4) 0 (0) 0.639
P 0.337
Dopamine agonists
Baseline 0 (0) 0 (0) 0 (0) 1.000
3-year follow-up 2 (8) 2 (7) 0 (0) 0.382
P 0.046
Melatonin
Baseline 0 (0) 0 (0) 0 (0) 1.000
3-year follow-up 7 (27) 3 (11) 4 (13) 0.290
P 0.001
Opioids
Baseline 2 (8) 3 (11) 1 (3) 0.507
3-year follow-up 1 (4) 0 (0) 2 (7) 0.643
P 0.190
NSAIDS, paracetamolb
Baseline 8 (31) 4 (15) 7 (23) 0.384
3-year follow-up 16 (62) 12 (44) 15 (50) 0.447
P < 0.001
Antihistamines
Baseline 4 (15) 1 (4) 2 (7) 0.330
3-year follow-up 4 (15) 1 (4) 2 (7) 0.330
P 1.000
Anticholinergics
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BZD withdrawal persistence remained at one-third com-
pared to baseline in all groups for up to 1 year [25].
However, no direct comparisons between previous stud-
ies can be made due to different withdrawal methods
and follow-ups times.
Why does BZDA withdrawal induce increased use of
other CNS medications? First, hypnotic drugs have a
strong placebo effect [26]. Second, it can be hypothe-
sized that BZDA withdrawal reveals previously untreated
conditions. The increase in symptomatic medications
can be explained by such symptoms that had been eased
by BZDA. Insomnia may precede comorbid depression.
The undiagnosed depressive symptoms, depression, and
muscle aches or progressive osteoarthritis, as well as
sleep problems explain at least partially participants’
increased antidepressant use. By 3 years, melatonin
seems to have replaced BZDAs as the hypnotic for some
(27%) of the BZDA non-users. Interestingly, melatonin
itself, in a recent meta-analysis, did not improve BZDA
withdrawal [27]. The minor increase in low-dose prami-
pexole (dopamine agonist) use in BZDA non-users and
in irregular users may be related to its use for restless
legs which had contributed to sleep disturbances; in fact,
BZDAs may have masked previously unrecognized
symptoms of restless legs syndrome.
The main strengths of this study are its long follow-up
time of up to 3 years and the very high follow-up reten-
tion rate of participants (90%), of whom most had for a
lengthy period used zopiclone or zolpidem up until the
withdrawal. One potential weakness is the relative small
sample size that limits validity of conclusions and does
not allow comparisons between individual hypnotics.
Another potential weakness is that use of BZDAs and
other medications at the 6-month and 3-year follow-up
points was based on interview data verified from medical
records but not by blood- or urine drug determina-
tions. However, no significant discrepancy between
patient-reported BZDA use and plasma levels
emerged at baseline or at the one-month follow-up
point in these participants [15]. Additionally, we have
no data on the medications between the 6-month and
3-year follow-up points.
Conclusions
Psychosocially supported gradual BZDA withdrawal was
effective in discontinuation of long-term hypnotic use,
but withdrawal persistence decreased over time. At
3 years after withdrawal, nearly one-third of the previous
chronic users were BZDA-free, one-third used it irregu-
larly, and one-third continued nightly use. High BMI
seems to predict poor withdrawal persistence, but mela-
tonin given during the withdrawal month failed to
improve persistence results.
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